174 related articles for article (PubMed ID: 26296840)
1. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.
Akahori T; Sho M; Kinoshita S; Nagai M; Nishiwada S; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
World J Surg; 2015 Dec; 39(12):2975-82. PubMed ID: 26296840
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
[TBL] [Abstract][Full Text] [Related]
3. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
4. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
5. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
8. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
[TBL] [Abstract][Full Text] [Related]
9. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
Mizukami T; Kamachi H; Mitsuhashi T; Tsuruga Y; Hatanaka Y; Kamiyama T; Matsuno Y; Taketomi A
BMC Cancer; 2014 Sep; 14():687. PubMed ID: 25240521
[TBL] [Abstract][Full Text] [Related]
11. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
[TBL] [Abstract][Full Text] [Related]
12. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
[TBL] [Abstract][Full Text] [Related]
14. Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis.
Uchida Y; Masui T; Nagai K; Anazawa T; Yoshimura M; Uza N; Takaori K; Mizowaki T; Uemoto S
Surg Oncol; 2020 Dec; 35():527-532. PubMed ID: 33160278
[TBL] [Abstract][Full Text] [Related]
15. Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinoma.
Levolger S; van Vledder MG; Alberda WJ; Verhoef C; de Bruin RWF; IJzermans JNM; Burger JW
Clin Nutr; 2018 Oct; 37(5):1728-1735. PubMed ID: 28756039
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
Homma Y; Honda G; Sakamoto K; Kurata M; Honjo M; Hirata Y; Shinya S
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1166-1170. PubMed ID: 27760934
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression.
Murakami T; Homma Y; Matsuyama R; Mori R; Miyake K; Tanaka Y; Den K; Nagashima Y; Nakazawa M; Hiroshima Y; Ueda M; Tanaka K; Hoffman RM; Bouvet M; Endo I
J Surg Oncol; 2017 Sep; 116(3):416-426. PubMed ID: 28608409
[TBL] [Abstract][Full Text] [Related]
18. Does the computed tomography perfusion imaging improve the diagnostic accuracy in the response evaluation of esophageal carcinoma to the neoadjuvant chemoradiotherapy? Preliminary study.
Djuric-Stefanovic A; Saranovic D; Micev M; Stankovic V; Plesinac-Karapandzic V; Pesko P; Stojakov D; Sabljak P; Bjelovic M
J BUON; 2014; 19(1):237-44. PubMed ID: 24659670
[TBL] [Abstract][Full Text] [Related]
19. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.
Fujii T; Yamada S; Murotani K; Kanda M; Sugimoto H; Nakao A; Kodera Y
Medicine (Baltimore); 2015 Sep; 94(39):e1647. PubMed ID: 26426657
[TBL] [Abstract][Full Text] [Related]
20. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
